Oct

12

DNAPrint Genomics Inc. (Symbol: DNAP)

Filed Under Biotechnology & Drugs | Leave a Comment

Last week I just purchased 3,000 shares of DNAPrint Genomic Inc. (Symbol: DNAG). Didn’t really cost me a lot of money since it’s traded around 1 cents/share. Want to know why did I invest in this company? Well…Let me tell you a little bit information about this company.

DNAPrint Genomic Inc. is a genomics science company, focusing on the sale of unique proprietary genetic testing products and services. They are currently focusing their efforts in four distinct markets:
1. Pharmacogenomics Market
The testing of individuals to predict their genetic predisposition to drug response is known as pharmacogenomics. Pharmacogenomics enables physicians to tailor drug therapies (formulation and dosage) for individuals based on their genetic composition, increasing rates of therapeutic success and decreasing rates of adverse side effects. Drug discovery companies are beginning to use pharmacogenomics technologies to develop drugs that are suitable for subpopulations based upon their genetic composition.

2. Forensics DNA Testing Market
Testing DNA to create a physical profile of crime suspects is a new market based on evolving technologies. Common hereditary traits such as skin pigmentation, eye color, hair color, earlobe attachment and height can be predicted through analysis of DNA sequences. DNAPrintTM believes it is the first company to use DNA evidence to successfully profile a crime suspect by predicting that suspect’s continental origin.

3. Consumer DNA Products Market
There is an established market of consumers who recreationally research their genealogy and ancestral origin. Additionally, there is a market for paternity tests and other tests related to lineage. DNAPrintTM serves both of these consumer market segments through direct sales and independent distributors.

4. Contract Service Outsourcing Market
DNAPrintTM provides universities and drug discovery companies with genotyping services. The service provides our clients with the ability to screen efficiently and effectively for genes that may be responsible for certain human traits and/or disease states. (Source: http://www.dnaprint.com/)

Currently the share is traded at $0.015/share, which is unbelievably cheap. Obviously this is more like long-term investment since there are not a lot of companies are doing this technology yet. If you’re still not convinced that this company is a good investment, check out these news releases:

1. DNAPrint(TM) genomics, Inc. Agrees to Acquire Majority Ownership in German Pharmaceutical Company Biofrontera AG; Secures $35 Million Equity Commitment from Dutchess Private Equities Fund, L.P.
http://www.biospace.com/news_story.cfm?StoryID=17515920&full=1

2. DNAPrint Presents Forensics Discoveries; New Products Could Transform The Landscape Of DNA Testing
http://www.dnaprint.com/pr_6_27.htm

3. DNAPrint launches ‘ethnicity’ test
http://www.drugresearcher.com/news/news-NG.asp?id=54499

Quote of the Day:
If we find a company we like, the level of the market will not really impact our decisions. We will decide company by company. We spend essentially no time thinking about macroeconomic factors. - Warren Buffett

← Previous Page